Abstract
The field of quantitative structure activity relationships (QSAR) has evolved into an integral tool for pharmaceutical discovery. It is presently an accessible technology, as can be shown by the number papers which are easily found through PubMed literature searches. At one level, QSAR is used routinely and invisibly as an aid for the bench chemist for logP, logS, pKa/pKb, metabolic stability and other such properties. Chemoinformaticians and computational chemists develop models from scratch for less routine purposes associated with lead optimization around a single target or library design around a target family such as kinase, ion channel or GPCR inhibitors. Regardless of the differences in frequency of use and the end user, any successful QSAR is successful because it rests on appropriate mathematics linking valid data and relevant descriptors. Though success is defined by the end user, the QSAR originator is well advised to validate his model and understand how it performs in different situations. The present review will cover QSAR from the ground up as it is used in pharmaceutical research environments. It will focus towards larger dataset methodologies (a minimum 100 of compounds) and by consequence will focus on 2D descriptors. It will start with the critical base of data, descriptors, equations and validation methods. It will review the broadly used and invisible QSARs for logP, pKa/pKb and metabolic stability. The review will then present progress in QSARs of broad interest which are under active development: 1) hERG liability models, 2) modeling for 2a) drug-likeness and related properties, 2b) kinase ligand likeness and 2c) GPCR ligand likeness.
Keywords: QSAR, QSAR validation, QSAR 2D descriptors, Focus library
Current Topics in Medicinal Chemistry
Title: QSAR in the Pharmaceutical Research Setting: QSAR Models for Broad, Large Problems
Volume: 10 Issue: 6
Author(s): D.G. Sprous, R.K. Palmer, J. T. Swanson and M. Lawless
Affiliation:
Keywords: QSAR, QSAR validation, QSAR 2D descriptors, Focus library
Abstract: The field of quantitative structure activity relationships (QSAR) has evolved into an integral tool for pharmaceutical discovery. It is presently an accessible technology, as can be shown by the number papers which are easily found through PubMed literature searches. At one level, QSAR is used routinely and invisibly as an aid for the bench chemist for logP, logS, pKa/pKb, metabolic stability and other such properties. Chemoinformaticians and computational chemists develop models from scratch for less routine purposes associated with lead optimization around a single target or library design around a target family such as kinase, ion channel or GPCR inhibitors. Regardless of the differences in frequency of use and the end user, any successful QSAR is successful because it rests on appropriate mathematics linking valid data and relevant descriptors. Though success is defined by the end user, the QSAR originator is well advised to validate his model and understand how it performs in different situations. The present review will cover QSAR from the ground up as it is used in pharmaceutical research environments. It will focus towards larger dataset methodologies (a minimum 100 of compounds) and by consequence will focus on 2D descriptors. It will start with the critical base of data, descriptors, equations and validation methods. It will review the broadly used and invisible QSARs for logP, pKa/pKb and metabolic stability. The review will then present progress in QSARs of broad interest which are under active development: 1) hERG liability models, 2) modeling for 2a) drug-likeness and related properties, 2b) kinase ligand likeness and 2c) GPCR ligand likeness.
Export Options
About this article
Cite this article as:
Sprous D.G., Palmer R.K., Swanson J. T. and Lawless M., QSAR in the Pharmaceutical Research Setting: QSAR Models for Broad, Large Problems, Current Topics in Medicinal Chemistry 2010; 10 (6) . https://dx.doi.org/10.2174/156802610791111506
DOI https://dx.doi.org/10.2174/156802610791111506 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal Current Approaches for the Treatment with Thyroid Hormone Analogs
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
Current Cardiology Reviews Application of Multivariate Linear and Nonlinear Calibration and Classification Methods in Drug Design
Combinatorial Chemistry & High Throughput Screening Cardiac Monitoring in Patients with Syncope: Making that Elusive Diagnosis
Current Cardiology Reviews Stem Cells as a Novel Tool for Drug Screening and Treatment of Degenerative Diseases
Current Pharmaceutical Design The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy
Current Cardiology Reviews Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Computational and Functional Analysis of the Androgen Receptor Antagonist Atraric Acid and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review
Current Drug Metabolism Treatment of Tachycardia in Hypertension: Where Do We Stand Now?
Current Hypertension Reviews Catestatin: A Master Regulator of Cardiovascular Functions
Current Medicinal Chemistry The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS
Current Cardiology Reviews Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications
Current Pharmaceutical Design Augmentation of Creatine in the Heart
Mini-Reviews in Medicinal Chemistry Novel Strategies for the Management of Acute Decompensated Heart Failure
Current Cardiology Reviews COVID-19: An Update on Pathogenesis and Treatment
Current Pharmaceutical Design Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Cell Therapy for Cardiac Regeneration after Myocardial Infarct: Which Cell is the Best?
Cardiovascular & Hematological Agents in Medicinal Chemistry Stress Echocardiography
Current Pharmaceutical Design